Topics

NXTC Catapults To New High, SUPN Fails Phase 3 Trial, PTLA Delivers Strong Q3

00:49 EST 6 Nov 2019 | RTTNews

Today's Daily Dose brings you news about the FDA approval of Crescita's enhanced formulation of Pliaglis; failure of Supernus' phase III trial of SPN-810 for the treatment of Impulsive Aggression (IA) in ADHD; NextCure's promising data from phase I portion of its ongoing phase I/II trial of NC318 in advanced or metastatic solid tumors; quarterly financial results of Portola, and KORU Medical.

Original Article: NXTC Catapults To New High, SUPN Fails Phase 3 Trial, PTLA Delivers Strong Q3

NEXT ARTICLE

More From BioPortfolio on "NXTC Catapults To New High, SUPN Fails Phase 3 Trial, PTLA Delivers Strong Q3"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...